Elon Musk Says mRNA Has 'Tremendous Promise,' Turning Disease Into a 'Software Problem,' as Moderna Stock Rockets 177% on Cancer Vaccine Breakthrough
In brief
Moderna and Merck’s Phase 3 melanoma vaccine win validates mRNA oncology, sending shares soaring and boosting confidence in the platform’s future.